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Abstract
Background. Infliximab is a biological drug used for the treatment of Crohn’s disease in children.
Objectives. The aim of this retrospective study was the estimation of effectiveness and safety of infliximab in the 
treatment of Crohn’s disease with perianal fistulas in children.
Material and Methods. Analysis comprised 50  children with Crohn’s disease with perianal fistulas aged 9 to 
18  years (16  girls and 34  boys) who failed to respond to conventional therapy. The  children were divided into 
two groups: the first group contained 23 children with simple fistulas and the second – 27 children with complex 
fistulas. All children were treated with infliximab, administered in the dose of 5 mg per kilogram of the body mass. 
In the induction phase infliximab was administered at weeks 0, 2 and 6 and after clinical response in maintenance 
phase the drug was administered every 8 weeks; together for 12 months.
Results. In  76% of children after induction therapy with infliximab and in 71.87% after maintenance therapy 
the complete closure of fistula occurred. During the first year after the treatment a  recurrence of a  fistula was 
observed in 30.43% of the children. In two children anaphylactic shock was observed during injection of infliximab. 
The remaining children tolerated the drug well.
Conclusions. The treatment with infliximab was effective in the majority of fistulazing Crohn’s disease and caused 
the closure of perianal fistula which improved quality of life (Adv Clin Exp Med 2016, 25, 3, 523–530).
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Crohn’s disease is a chronic inflammatory dis-
ease which can affect each part of the gastroin-
testinal system. Observed changes are segmental, 
comprise the whole intestinal wall and may lead to 
such complications as fibrosis, strictures and fistu-
las. Children older than 10 years are affected most 
frequently. In  25% of all cases the disease begins 
in patients who are younger than 20  years  [1–3]. 
The disease in children is characterized by abdom-
inal pain, chronic diarrhea, bloody stools, fever, ar-
rest of the growth and sexual development as well 
as perianal changes with abscesses, fistulas and ex-
traintestinal symptoms  [4–5]. According to Keljo 
et al. [6] frequency of perianal changes such as skin 
tags, fissures, fistulas, abscesses and rectal stric-
tures ranges from 13.6% to 62%. Palder et al. [7], 
in analysis of Crohn’s disease in 325 children, ob-
served that perianal changes had developed in 62% 
of them. The most frequent were: fissures (in 185 
cases, 51%), skin tags in 114 children (35%), fistu-
las in 41 children and rectal abscesses in 47 chil-
dren. According to Eglinton et  al.  [8] the risk of 
perianal changes development in the course of 
Crohn’s disease in children is 26.5%. Genotype 
analysis revealed a link of the risk with neutrophil 
cytosolic factor 4 (NCF4) gene compared with both 
non- and perianal Crohn’s disease patients. Other 
authors demonstrated the link of the development 
of fistulas in Crohn’s disease with such genes as 
IRGM (immunity related guanosine triphospha-
tase protein type M) and OCTN (carnitine, organ-
ic cathion transporter) localized on chromosome 
5q31 (IBD5)  [9–11]. Inflammatory process with-
in intestinal wall in patients with Crohn’s disease 
may lead to delamination of it and creation of fis-
tula. Fistulas can be present between large intes-
tine lumen and the skin in the perianal area; less 
frequently skin of abdomen, between intestinal lu-
men and urinary bladder or vagina and between 
the large and small intestinal loops. Disturbed 
drainage of inflammatory content of the fistula 
leads to congestion and to creation of an abscess.
Clinical course of Crohn’s disease with peri-
anal changes depends on the type of changes, the 
presence of a rectal or anal stricture, which occur as 
a consequence of long-term inflammation. Anal fis-
tulas are completely curable, condylomata are usu-
ally of mild character and partially diminish during 
treatment. Non-inflammatory condylomata are not 
painful and do not require treatment; moreover, 
they should not be removed surgically since they 
heal poorly and reoccur. In the patients with uncer-
tain diagnosis, speciments from condylomata can 
be sampled and examined for granulomas, which 
are present in 30% of the patients with Crohn’s dis-
ease. Treatment of fistulas is most difficult which in 
turn may lead to constipation, stool incontinence, 
recurrent infections and sepsis as well as to a  de-
crease in life quality and surgery [6, 12].
Fistulas can be divided into simple and com-
plex  [13]. Simple fistuals are localized predomi-
nantly closer to the margin of the anus, have short 
canal and there is no abscess present. Complex 
fistuals may be numerous, branched, they are ac-
companied or not by the abscess and their exter-
nal orifice is localized further from the anal orifice. 
Treatment of fistulas involves antibiotics, thiopu-
rines, metotrexate and biological drugs as well as 
surgical treatment. Up to 50% of fistulas that are 
superficial and limited to the anal canal is self-heal-
ing. Contrary, complex fistulas, both with or with-
out abscess, vaginal, recto-vesical and interloop 
fistulas are difficult to treat and very frequently re-
quire surgical treatment. Various scales of activi-
ty and classifications have been used in Crohn’s 
disease with fistulas; they evaluated not only the 
activity of fistulas but also other perianal chang-
es [14–18]. Present et al. [19] described simple and 
reliable scale of activity of fistulas in Crohn’s dis-
ease. In that scale they took into consideration the 
closure of the fistula and improvement or remis-
sion. Lack of exudation during a gentle push of the 
vicinity of fistula has been regarded as the closure. 
Improvement has been defined as the closure of 
more than 50% of fistulas which were present at the 
initial point or decrease of mucous secretion. Re-
mission has been defined as the closure of all fistu-
las which persisted at least during two visits of the 
patient. National Health Fund therapeutic program 
of treatment of Crohn’s disease with fistulas in chil-
dren aged 6 to 18 years includes treatment with in-
fliximab in all patients who have not responded to 
antibiotics, immunosuppressive drugs and surgical 
treatment regardless to disease activity [21].
Objective
The  objective of this retrospective study was 
to estimate the efficiency and safety of the treat-
ment with infliximab of Crohn’s disease with peri-
anal fistulas in children who have not responded to 
conventional therapy.
Material and Methods
From the multicenter study on the treat-
ment with infliximab of children with Crohn’s 
disease conducted in the years 2004–2013 in Po-
land, a  group of children with fistualas was se-
lected [21, 22]. Two hundred twenty one individ-
ual patients questionnaires were collected from 
10 centers in which the treatment with infliximab 
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was conducted. In 55 (24.88%) children from this 
group fistulas were present; in 22.62% – perianal 
fistulas and in 2.25% –  fistulas with other local-
ization. The  results of the treatment with inflix-
imab of 153  children with Crohn’s disease with-
out fistulas were described in another paper [22]. 
In this study we analyzed the treatment with inf-
liximab of 50 children with Crohn’s disease with 
simple and complex fistulas. In 33 out of 55 chil-
dren (60%) perianal fistulas were present, in 17 
(30.9%) perianal fistulas with an abscess and in 
same cases intestine interloop, to the vagina or to 
the urinary bladder (Table 1).
Diagnosis of Crohn’s disease was based on 
Porto Criteria [23]. Beside these criteria in 16 pa-
tients the diagnosis was confirmed by MR enterog-
raphy, in four by enteroclysis and in two – by fistu-
lography. In four children the rectal structure was 
observed. In  all 50  children with Crohn’s disease 
inflammatory changes were localized in the ileum 
and colon. According to National Health Fund rec-
ommendation, the criterion of qualification to the 
treatment with infliximam program was the pres-
ence of fistula independently of Pediatric Crohn’s 
Disease Activity Index), age of patients from 6 to 
18 years and failure to respond to previous treat-
ment with antibiotics, immunosuppressive drugs 
as well as failure of surgical treatment [21]. All the 
children in our study aged from 9 to 18 years were 
divided into two groups. 23 children with simple 
fistuals were assigned to the group I, and 17 chil-
dren with complex fistulas to the group II. Com-
plex fistulas, branched or with accompanying ab-
scess were relatively common.
In  the induction phase of the treatment inflix-
imab was given in the dose 5 mg/kg of body mass at 
weeks 0, 2 and 6. All children in whom clinical re-
sponse was observed, meaning that the clinical activ-
ity of disease decreased or fistula closed, were given 
maintenance therapy: 5 mg/kg of infliximab, every 
8 weeks for the period of 12 months. In all patients 
clinical activity of the disease was assessed before and 
after the treatment using PCDAI. In 38 children C-
reactive protein (CRP) concentration was measured, 
in 33 children endoscopic activity was assessed ac-
cording to Simplified Endoscopic Activity Score for 
Crohn’s Disease (SES-CD) and in 44 children Body 
Mass Index – BMI was calculated [24, 25].
All results were subjected to statistical analysis. 
In descriptive part the means and standard devia-
tions were calculated. The results of the treatment 
in the groups with simple and complex fistulas 
were compared using c2 test and the significance 
of difference between groups before and after the 
treatment of dependent data of clinical activi-
ty (PCDAI, CRP, SES-CD, BMI) was assessed by 
t-student test. Correlation between PCDAI, CRP 
and SES-CD were assessed using Pearson’s corre-
lation test. All differences were regarded as statis-
tically significant when p-value was smaller than 
0.05. STATISTICA  10PL package was used in all 
statistical calculations. Approval from the Wro-
claw Medical University Bioethical Commission 
was obtained to conduct the study.
Results
Table  2 presents the characteristics of treat-
ed children. Crohn’s disease with fistulas was di-
agnosed more frequently in boys than in girls: 
34 (68%) vs. 16 (32%) (p  <  0.05). Only two chil-
dren were younger than 10  years, the remain-
ing 48  children were 10 to 18  years old. The  du-
ration of the disease ranged from 1 to 60 months 
(16.09  ±  15.71  months). In  12  patients concomi-
tant diseases or extraintestinal diseases were ob-
served. A  brother of one of our patients was al-
so diagnosed with Crohn’s disease. In 11 children 
(22.0%) growth retardation was observed and 
in 4 (8.0%) sexual development was also retarded. 
Any statistical differences between children with 
simple and complex fistulas were observed.
Results of induction therapy are presented in 
Table 3. In 38 children (76.0%) the closure of fis-
tula was observed and in 4 partial improvement 
(decrease of exudation). Lack of improvement was 
observed in 6  children (12.0%) and in 2  children 
(4%) an anaphylactic shock occurred during infu-
sion of infliximab. In one child varicella infection 
appeared during the treatment. In 2 children reoc-
currence of fistula was observed after third dose of 
infliximab. There were no statistical differences in 
the treatment results between children with simple 
and complex fistulas.
Results of induction and maintenance treat-
ment in 32  children are presented in Table  4. 
Table 1. Localization of 55 fistulas in Crohn’s disease 
in 221 children
Fistula localization No. of children
n %
Perianal fistulas 33  60.00
Perianal fistulas and abscess 17  30.90
Ileocutaneous fistula  2   3.64
Interloop fistula  1   1.82
Rectovaginal fistula  1   1.82
Recto-vesical fistula  1   1.82
Total 55 100.00
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In  23  children (71.78%) the closure of fistula was 
observed; in 4  children (12.5%) partial closure oc-
curred. In 5 (15.62%) children reoccurrence of fistu-
la during maintenance treatment was observed and 
17 children had to be surgically treated due to fistula 
or abscess. During one year after completion of the 
treatment, reoccurrence of fistula was observed in 
7 out of 23 children (30.43%). Comparison of chil-
dren with simple and complex fistulas demonstrated 
a statistical difference only in the number of surger-
ies which was greater in the case of complex fistulas.
Analysis of clinical activity of Crohn’s disease 
in children with simple or complex fistulas dem-
onstrated a statistically significant decrease of clin-
ical activity and concentration of CRP after induc-
tion and maintenance therapy as compared to the 
start of therapy. Endoscopic activity of the disease 
also decreased after 12-months treatment and BMI 
increased (Table 5).
Comparison of PCDAI, CRP, endoscopic ac-
tivity and BMI between children with simple fistu-
la and children with complex fistula did not show 
a statistically significant difference (Table 6).
An analysis of correlations between assessed 
parameters demonstrated a  connection between 
the age of patients and BMI. BMI increased to-
gether with age both in children with simple and 
with complex fistulas. A  positive correlation was 
also observed between disease clinical activity 
(PCDAI), endoscopic activity (SES-CD) and CRP 
during the first examination before introduction of 
infliximab therapy. Along with the increase of PC-
DAI endoscopic activity and CRP in children with 
simple and complex fistulas were also increasing.
Table 2. Characteristics of the 50 children with perianal fistulas in Crohn’s disease treated with infliximab
Parameter No. of children treated with infliximab
total simple fistulas  
23 children
complex fitulas  
27 children
p-value































Inflammatory bowel diseases in family  1  2.0  1  4.34  0 –
Concommitant diseases  5 10.0  2  8.69  3 11.11 ns.
Extraintestinal manifestations  7 14.0  3 13.04  4 14.82 ns.
Growth retardation 11 22.0  6 26.08  5 18.51 ns.












ns. – statistically not significant.
Table 3. Results of induction infliximab therapy in 50 children with perianal fistula in Crohn’s disease







n % n % n %
Closure of fistula 38 76.0 18 78.26 20 74.07 ns.
Partial improvement  4  8.0  1  4.34  3 11.11 ns.
Lack of imrpovement  6 12.0  3 13.04  3 11.11 ns.
Anaphylactic shock  2  4.0  1  4.34  1  3.70 ns.
Relapse of disease after 3rd dose of infliximab  2  4.0  1  4.34   1  3.70 ns.
ns. – statistically not significant.
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Table 4. Results of induction and maintenance infliximab therapy in 32 children with perianal fistula Crohn’s disease







 n %  n %  n %
Closure of fistula 23 71.87 10 71.42 13 72.22 ns.
Partial closure  4 12.5  1  7.14  3 16.66 ns.
Reccurence of fistula and/or abscess during 
maintenance treatment
 5 15.62  3 21.42  2 11.11 ns.
Surgical treatment (fistulas, abscesses) 17 53.12  1  7.14 16 88.88 < 0.05
Reccurence of fistula within one year after 
treatment
 7/23 30.43  3/10 30.00  4/13 30.76 ns.
Table 5. Comparison of clinical activity (PCDAI), endoscopic activity (SES_CD), CRP and BMI in children with Crohn’s 
disease with simple and complex fistulas treated with infliximab (I – before treatment, II – after induction treatment, III 
– after maintenance treatment
Parameter Simple fistulas Complex fistulas


























































Table 6. Comparison of clinical activity (PCDAI), endoscopic activity (SES_CD), CRP and BMI in children with Crohn’s 
disease with simple and complex fistulas treated with infliximab (I – before treatment, II –10 weeks of treatment, 
III –54 weeks of treatment
Parameter Simple fistulas Complex fistulas p-value
x ± s x ± s










































Crohn’s disease is a chronic inflammatory dis-
ease of the intestines without an elucidated etiolo-
gy. It  is characterized by periods of remission and 
relapse. Its chronic inflammatory activity leads to 
the creation of fistulas and abscesses which in chil-
dren can be sometimes observed at the time of dis-
ease diagnosis. Clinical course of the disease which 
begins in childhood is particularly severe; the dis-
ease is localized most frequently in the terminal part 
of the ileum and colon and frequently leads to fistu-
las localized mainly in the perianal area. Therefore, 
the main objective of disease management should 
be long-term remission and prevention of com-
plications such as intestinal constriction and fistu-
las, limitation of hospital admissions and surgical 
procedures as well the improvement of life quality. 
Commonly used drugs such as azathioprine, 6-mer-
captopurine and methotrexate may slightly dimin-
ish the risk of complications and delay them only in 
some cases. Biological treatment with TNF-alfa in-
hibitors improve the condition of intestinal muco-
sa, and diminish the number of hospital admissions 
and surgeries [20, 26]. The results of the treatment 
of fistulas are also improved [6, 13, 17, 19, 27–31]. 
However, there is a  lack of credible studies on the 
prevention of fistulas in Crohn’s disease in children.
Our analysis demonstrated that Crohn’s dis-
ease with fistulas was present in 96% of children 
older than 10 years. Only in two children the dis-
ease was present at the age of 9–10  years. Boys 
were affected more frequently than girls (68.0% vs. 
32.0%, p < 0.01) and the duration of Crohn’s disease 
ranged from 1 to 60 months (average 16.09 ± 15.71 
months). There were no significant differences be-
tween the age and duration of the disease between 
children with simple and complex fistulas.
Healing of abscess and closure of fistula are 
the principal goals of the management of Crohn’s 
disease with fistulas. The presence of abscess, both 
superficial and deep, usually requires a  surgical 
incision, drainage as well as antibiotics, immuno-
suppressants or monoclonal antibodies anti-TNF- 
-alfa. Good results were obtained by the means of 
antibiotics: metronidazol and cipropholxacine [32]. 
Korelitz et al. [33] and Kirschner et al. [34] demon-
strated positive results of the treatment with 6-mer-
captopurine and azathioprine in adults. Great ex-
pectations are connected to biological treatment. 
Numerous authors analyzing the results of inflix-
imab therapy in adults with Crohn’s disease ob-
served that in more than a half of the patients fistu-
las were completely closed after induction therapy; 
slightly worse results were seen after maintenance 
therapy [19, 27, 29, 30, 35, 36]. Crandall et al. [37] 
obtained good results with infliximab in treating 
Crohn’s disease with fistulas in children at 54th 
week of the treatment. In  16 (73%) children they 
obtained a clinical response; from these children in 
15 a complete closure of fistula was observed and 
in one child –  partial closure. We  obtained simi-
lar results. After a year of the treatment in 71.87% 
a  complete closure of fistula was observed and in 
12.5% – partial closure. In 30.43% of the children 
reoccurrence of fistula was observed. Other authors 
also describe good results of the treatment with in-
fliximab of fistulas in children  [38, 39]. De Rid-
der et al.  [39] obtained a  long clinical response in 
56% of the patients. Retrospective review of litera-
ture demonstrated that in 70% of the patients treat-
ed with infliximab fistula was closed within three 
months. In another study the authors assessed both 
strategies: “top down” vs. “step up”  [40]. In  chil-
dren with fistulas treated with infliximab with “top 
down” strategy, at 8th week a  complete closure of 
the fistula was observed in 58% of the children and 
only in 17% with “step up” strategy. After a year of 
treatment with infliximab fistulas were closed in 
50% of patients in “step up” strategy compared to 
100% in “top down” [40]. However, these interest-
ing results are based on a small number of patients. 
It is worth noting that ECCO experts do not recom-
mend anti-TNF-alfa drugs as the first line drugs in 
monotherapy. Concomitant use of thipurines, an-
tibiotics and surgical treatment is required [1, 26].
In  the assessment of the treatment, not only 
the lack of exudation from the fistula, which can be 
a sign of external orifice closure, but also a meticu-
lous assessment of the canal of fistula is important. 
Frequently, despite the lack of exudation from the 
fistula, its canal remains intact and the activity of 
the fistula returns after the completion of treatment, 
which was frequently observed in children treated 
by us. MRI and transrectal ultrasound study may be 
helpful in the assessment of treatment [13, 42].
In the summary it should be emphasized that in 
24.8% of children with Crohn’s disease fistulas, main-
ly perianal, were present. Fistulas were observed most 
frequently in boys older than 10 years. Among peri-
anal fistulas 46% were simple fistulas and 54% – com-
plex fistulas, often with the presence of an abscess. 
Induction and maintenance therapy with infliximab 
confirmed its efficiency in the treatment of fistulas. 
After 54 weeks of treatment a total closure of fistula 
was observed in 71.8% of the children and in 12.5% 
– a partial closure. In 30.34% of the children reoccur-
rence of fistula was observed within a year after treat-
ment. The treatment with infliximab should be rec-
ommended as a treatment of active perianal fistulas 
after inefficient treatment with antibiotics, thopurines 
or surgical treatment. The treatment with infliximab 
was safe, decreased the number of hospitalizations 
and improved the quality of life of the patients.
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